SAN RAMON, Calif.–(BUSINESS WIRE)– BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure, announced today publication of baseline and 12-month comparative data demonstrating the durability of its Revivent Myocardial Anchoring System in the first 11 patients treated with the device. Published in the European Journal of Cardio-Thoracic Surgery (EJCTS), these patients sustained a mean reduction in left ventricular end-systolic volume index (LVESVI), the key prognostic measure for heart failure, to 43.9 mL/m2, well below the 60mL/m2 threshold recently defined as providing a survival benefit in heart failure patients.1,2 The Company also announced that the number of heart failure centers trained to perform the LIVE procedure has expanded to 20 leading centers throughout Western Europe. “The extent of volume reduction achieved, and more importantly maintained at one year, using the Revivent System is comparable with, and in some cases exceeds, the results achieved in multiple clinical studies using a conventional surgical approach to reducing the volume of the left ventricle,” said Andrew S. Wechsler, M.D., professor of Cardiothoracic Surgery at Drexel University College of Medicine in Philadelphia, Penn., U.S.A. “These results demonstrate that effective volume reduction, using a less invasive approach, provides meaningful clinical [...]
↧